

# HOMBURGER ADVISED SANTHERA ON ITS FINANCING

*Posted on 8 March 2023*



**Categories:** [Capital Markets](#), [Corporate](#)

**Tags:** [Anna Delia Lohmann](#), [Daniel Häusermann](#), [Eduard de Zordi](#), [Fabio Anceschi](#), [Jasmin Künzle](#), [Romain Fakhoury](#), [Slider](#), [Stefan Oesterhelt](#)



**Santhera Pharmaceuticals Holding** announced a private placement of shares and an amendment of its existing financing with funds managed by **Highbridge Capital Management** to provide up to CHF 22.2 million in aggregate, subject to certain milestones and conditions. Concomitant with this transaction, Santhera will form a strategy committee focusing on evaluating all strategic options for the company.

In addition, Santhera issued 40 million shares in an ordinary capital increase, 37 million of which will be held in treasury for the time being.

The **Homburger** team was led by **Daniel Häusermann** (corporate / m&a, capital markets, pictured) and included **Eduard De Zordi** (capital markets), **Stefan Oesterhelt** (tax), **Jasmin Künzle** and **Romain Fakhoury** (both corporate / m&a, capital markets), as well as **Anna Delia Lohmann** and **Fabio Anceschi** (both corporate / m&a).